Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Inhibikase Therapeutics' (IKT) quarterly Capital Expenditures came in at $13399.0 in Q1 2025, down 93.31% on a QoQ basis from $200166.0 in Q3 2022.

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025) Analysis & Trends

Inhibikase Therapeutics (IKT) has 2 years of Capital Expenditures data on file, last reported at $13399.0 in Q1 2025.

On a quarterly basis, Capital Expenditures changed N/A year-over-year to $13399.0 in Q1 2025; TTM through Dec 2025 was $13399.0, a N/A change from a year earlier, with the FY2025 full-year figure at $13399.0, changed N/A from the prior year.
Capital Expenditures for Q1 2025 stood at $13399.0, down from $200166.0 in the prior quarter.
Over the last five years, Capital Expenditures for IKT reached as high as $200166.0 in Q3 2022 and fell as low as $13399.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Inhibikase Therapeutics	55.25 Mn	-115.12 Mn	-	-

Download Data